文献速递泌尿男性生殖肿瘤

根治性前列腺切除术后生化复发:大分割加速与标准挽救放疗的III期随机对照试验

Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.
PubMed 文献 · J Clin Oncol · 2026-08-25

该III期随机试验纳入316例中高危前列腺癌根治术后生化复发患者,随机接受大分割放疗(65 Gy/26次)或常规放疗(66 Gy/33次)。中位随访52.6个月,4年生化无进展生存率分别为80.1%和78.1%,无显著差异;大分割组≥2级胃肠道毒性累积发生率更高(7.9% vs 0.7%),但所有病例末次随访时已缓解。

要点

  • 大分割放疗4年bPFS未优于常规放疗(80.1% vs 78.1%)。
  • 两组DMFS和CSS无显著差异,患者报告生活质量相当。
  • 大分割组≥2级胃肠道毒性更高(7.9% vs 0.7%),多见于未使用直肠气囊者。

核心结论

  • 大分割放疗4年bPFS未优于常规放疗,但肿瘤学结局、毒性和生活质量相当,可作为挽救治疗的可选方案。

研究设计与样本

  • 2019至2021年纳入316例中高危前列腺癌根治术后生化复发患者,随机接受大分割放疗(65 Gy/26次)或常规放疗(66 Gy/33次)。
  • 放疗靶区为前列腺床, elective盆腔淋巴结照射由放疗医师决定,采用调强放疗和每日图像引导。
  • 主要终点为生化无进展生存(bPFS),次要终点包括无远处转移生存(DMFS)、前列腺癌特异性生存(CSS)、毒性和患者报告生活质量。

主要发现

  • 放疗前中位PSA为0.36 ng/mL(IQR 0.24-0.49 ng/mL),中位随访52.6个月。
  • 4年bPFS率大分割组80.1%,常规组78.1%;4年DMFS率分别为91.7%和91.0%;CSS均为100%。
  • 4年≥2级胃肠道毒性累积发生率大分割组7.9%,常规组0.7%,主要见于未使用直肠气囊者,末次随访时均缓解。
  • 患者报告生活质量结局两组相当。

临床怎么用

  • 对于根治性前列腺切除术后生化复发的中高危患者,大分割放疗(65 Gy/26次)可作为常规放疗的可行替代方案。
  • 考虑大分割放疗时需关注胃肠道毒性风险,尤其是未使用直肠气囊的患者。

局限性

  • 原文未明确报告研究的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare hypofractionated radiotherapy (RT) with conventional RT for treating biochemical recurrence following radical prostatectomy. METHODS: Between 2019 and 2021, 316 patients with intermediate- to high-risk prostate cancer were randomly assigned to receive salvage RT with either 65 Gy in 26 fractions (hypofractionated RT, HYPO) or 66 Gy in 33 fractions (conventional RT, CONV). RT was delivered to the prostate bed, with elective pelvic nodal irradiation performed at the discretion of radiation oncologists. Intensity-modulated RT with daily image guidance was used. The primary end point was biochemical progression-free survival (bPFS). Secondary end points included distant metastasis-free survival (DMFS), prostate cancer-specific survival (CSS), toxicity profiles, and patient-reported quality-of-life. RESULTS: One hundred fifty-one patients (51.2%) received androgen deprivation therapy, and 202 (68.5%) underwent elective nodal irradiation. Endorectal balloons were used in 186 men (63.1%). The median pre-RT prostate-specific antigen level was 0.36 ng/mL (IQR, 0.24-0.49 ng/mL). After a median follow-up of 52.6 months, the 4-year bPFS rates were 80.1% and 78.1% in the HYPO and CONV arms, respectively. There were no significant differences in DMFS (91.7% v 91.0%) and CSS (100% v 100%). The 4-year cumulative incidence of grade ≥2 GI toxicity was higher in the HYPO arm (7.9% v 0.7%), predominantly among patients without an endorectal balloon; all cases were resolved by the last follow-up. Patient-reported quality-of-life outcomes were comparable. CONCLUSION: bPFS was not superior in the HYPO arm at 4 years. However, given the comparable oncologic outcomes, toxicity profiles, and quality-of-life measures, hypofractionated RT may be considered a viable alternative in the salvage setting. Further research is needed to determine whether the use of an endorectal balloon reduces GI toxicity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Song Y, Park W, Pyo H, et al. Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial. J Clin Oncol. 2026. PMID: 42641124. doi:10.1200/JCO-25-02234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。